Global Cystic Fibrosis Therapeutics Market 2018-2022
About Cystic Fibrosis Therapeutics
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.
Technavio’s analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cystic Fibrosis Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global cystic fibrosis therapeutics market: AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is strategic collaborations. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the efficacy of products has already been demonstrated, thereby cutting down on initial R&D expenditure.”
According to the report, one driver in the market is improved diagnostic technologies. CF is a genetically inherited disease. Several diagnostic tests are available to detect the disease. Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests. Growing investment in and awareness about genetic diseases are expected to lead to improved diagnostic technologies, which will drive the growth of the market.
Further, the report states that one challenge in the market is drug discontinuation. Discontinuation of drugs from the development stage or from the market after their launch is a major challenge for investors and drug manufacturers. The discontinuation of drugs from the late-stage development or after approval due to reasons such as safety concerns leads to a significant financial loss for investors because of the high R&D and marketing costs involved in the process of drug development.
AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook